This paper delineates the purposes of Phase IV trials, considers some of the design issues specific to these trials, and questions the appropriateness of good clinical practice requirements in the Phase IV setting.
CPMP Working Party on Efficacy of Medicinal Products.Note for guidance. Good Clinical Practice for trials on medicinal products in the European Community. 111/3976/88, 1991.
2.
Drug Registration Requirements in Japan.4th edition. Tokyo: Yakuji Nippon Ltd; 1991.
3.
World Health Organization.Consultative document: proposed WHO guidelines for Good Clinical Practice (GCP) for trials on pharmaceutical products. WHO Drug Information.1992;6(4): 170–188.
4.
21 CFR (Code of Federal Regulations) parts 310–312, National Archives and Records Administration, revised as of April 1, 1993.
5.
SpilkerB.Marketing studies. Drug News & Perspectives.1990;3(6):369–371.
6.
WittePPostmarketing observational studies and phase IV trials in Germany. Applied Clin Trials.1993;2(7):54–60.
7.
VenuletJ.Potential role of postmarketing research. Drugs Exptl Clin Res.1987;XIII:673–683.
8.
ToscaniMRResnickG.Postmarketing studies: methods for implementation and potential use of data. Drug Inf J. 1992;26:261–265.
9.
BellRLSmithE. O'BrianClinical trials in post-marketing surveillance of drugs. Contr Clin Trials.1982;3:61–68.
10.
EdlavitchSA.Postmarketing surveillance methodologies. Drug Intel Clin Pharm.1988;22:68–78.
11.
EllenbergSSFinkelsteinDMSchoenfeldDA.Statistical issues arising in AIDS clinical trials. J Am Stat Assoc.1992;87:562–569.
12.
HakkarainenHHattabJRVenuletJ.Phase IV research by pharmaceutical companies. Pharmacopsychiat.1984;17:168–176.
13.
RayWAGriffinMRAvornJ.Evaluating drugs after their approval for clinical use. N Engl J Med.1993;329:2029–2032.
14.
ChadhaDR. Phase IV clinical trials. ESRA News & Views.1992;2:S14–S15.
15.
WengerNWhy community physicians should encourage their patients to participate in randomized clinical trials. Circulation.1978;58: 963–964.
16.
ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction. Lancet.1988;ii: 349–360.
17.
YusufSCollinsRPetoRIntravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials. Eur Heart J.1985;6:556–585.
18.
GISSI (Gruppo Italiano per lo Studio dela Streptochinasi Nell-Infarcto Miocardico).Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet.1986;i:397–401.
19.
RoyallRM.Ethics and statistics in randomized clinical trials. (With discussion). Stat Science.1991;6:52–88.
20.
AntmanEMLauJKupelnickBMostellerFChalmersTC.A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts. JAMA.1992;268: 240–248.
21.
HaenszelWLovelandDBSirkenMG.Lung cancer mortality as related to residence and smoking history. I. White males. J Natl Cancer Inst.1962;28:947.
22.
WaldronHACooksonRF.Avoiding the pitfalls of sponsored multicentre research in general practice. Br Med J.1993;307:1351–1354.
23.
StromBLMiettinenOSMelmonKL.Postmarketing studies of drug efficacy: when must they be randomized?Clin Pharmacol Ther.1983;34:1–7.
24.
ByarDPSchoenfeldDAGreenSBDesign considerations for AIDS trials. N Engl J Med.1990;323:1343–1348.
25.
TognoniGAlliCAvanziniFBettelliGColomboFCorsoRMarchioliRZussinoA.Randomised clinical trials in general practice: lessons from a failure. Br Med J.1991;303:969–971.
26.
LamasGAPfefferMAHammPDo the results of randomized clinical trials of cardiovascular drugs influence medical practice?N Engl J Med.1992;327:241–247.
27.
BoisselJP.Impact of randomized clinical trials on medical practices. Contr Clin Trials.1989;4: 120S–134S.
28.
BuyseM.Potential and pitfalls of randomized clinical trials in cancer research. Cancer Surveys.1989;8:91–105.
29.
BuyseM.The case for loose inclusion criteria in clinical trials. Acta Chir Belg.1990;90:129–131.
30.
YusufSHeldPTeoKKToretskyER.Selection of patients for randomized controlled trials: implications of wide or narrow eligibility criteria. Stat Med.1990;9:73–86.
31.
StenningS.The “Uncertainty Principle“: selection of patients for cancer clinical trials. In: Introducing new treatments for cancer.WilliamsCJ, Ed. New York: John Wiley; 1992.
32.
TempleR.Government viewpoint of clinical trials of cardiovascular drugs. Med Clinics N America.1989;73:495–509.
33.
FlemingTR.Treatment evaluation in active control studies. Cancer Treat Rep.1987;71:1061–1065.
34.
MakuchRWPledgerGHallDBJohnsonMFHersonJHsuJP.Active control equivalence studies. In: Statistical Issues in Drug Research and Development.PeaceKE, Ed. New York: Marcel Dekker; 1992.
35.
BuyseM.Regulatory vs public health requirements in clinical trials. Drug Inf J.1993;27:977–984.
36.
ISIS-3 (Second International Study of Infarct Survival) Collaborative Group.ISIS-3: a randomized comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet.1992;339:753–770.
CPMP Working Party on Pharmacovigilance.Draft Guideline for Marketing Authorization. Holders on company-sponsored post-marketing safety studies. 111/3176/93, 1993.
